ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Expansion of services in Rwanda is underway, including a nationally approved diagnostic and treatment protocol for CML, a national scale-up of cancer programs, expansion of the imatinib-procurement process through GIPAP, and diversification of in-country testing via Xpert BCR-ABL Monitor.